Previous 10 | Next 10 |
Blueprint gets European Union nod for Ayvakyt. Aquestive receives CRL for seizure clusters treatment Libervant. PMV Pharma makes impressive IPO debut, stock soars. For further details see: Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma ...
As expected, the European Commission approves Blueprint Medicines' ([[BPMC]] -0.7%) Ayvakyt (avapritinib) as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ((GIST)) harboring the platelet-derived growth factor receptor alpha ((P...
Blueprint Medicines Announces European Commission Approval of AYVAKYT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors -- First highly effective treatment option approved in Europe for PDGFRA D842...
Blueprint Medicines (BPMC) +3.8% in premarket, has announced top-line data from the Phase 1 EXPLORER and Phase 2 PATHFINDER clinical trials of AYVAKIT (avapritinib) in patients with advanced systemic mastocytosis ((SM)).In the EXPLORER trial, 53 patients were response evaluable, wit...
Blueprint Medicines Announces Positive Top-line Results from EXPLORER and PATHFINDER Trials of AYVAKIT™ (avapritinib) in Patients with Advanced Systemic Mastocytosis -- 76% confirmed ORR in EXPLORER, with a median duration of response of 38.3 months -- -- 75% confirme...
CAMBRIDGE, Mass. , Sept. 20, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced results from the ongoing ARROW clinical trial showing durable respo...
Blueprint Medicines ( BPMC +3.4% ) has reported new data from preclinical study of BLU-945, a precision therapy for patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). More news on: Blueprint Medicines Corporation, Healthcar...
CAMBRIDGE, Mass. , Sept. 17, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced preclinical proof-of-concept data for BLU-945, an investigatio...
So far this year, shares of Blueprint Medicines (NASDAQ: BPMC) haven't performed nearly as well as the company's research and development team. The company's already earned FDA approval for two new cancer drugs this year, but the stock is down about 17% this year. Is this a good biotech sto...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 08/7/2020. Please visit our Tracking Ole Andreas Halvorsen&...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 PR Newswire CAMBRIDGE, Mass. , July 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call an...
2024-07-10 04:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...